Puma Biotechnology (PBYI) Total Non-Current Liabilities (2019 - 2025)

Puma Biotechnology (PBYI) has 7 years of Total Non-Current Liabilities data on file, last reported at $86.0 million in Q4 2025.

• Quarterly Total Non-Current Liabilities fell 29.01% year-over-year to $86.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $86.0 million (down 29.01% YoY) and the FY2025 annual result came in at $86.0 million, down 29.01% from the prior year.
• Total Non-Current Liabilities fell to $86.0 million in Q4 2025, from $87.6 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $242.0 million in Q1 2021 to a low of $86.0 million in Q4 2025.
• A 5-year average of $163.9 million and a median of $163.9 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2021 — Total Non-Current Liabilities gained 16.27% — and 2025, when it sank 41.41%.
• Tracing PBYI's Total Non-Current Liabilities over 5 years: stood at $223.6 million in 2021, then dropped by 10.36% to $200.4 million in 2022, then declined by 11.7% to $177.0 million in 2023, then slumped by 31.58% to $121.1 million in 2024, then decreased by 29.01% to $86.0 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $86.0 million (Q4 2025), $87.6 million (Q3 2025), and $90.2 million (Q2 2025), per Business Quant data.